“The announcement goes into effect on January 2022, but the MOH has stated that they will begin accepting CSDT format ahead of time.”

David Vo
General Manager
Asia Actual VietNam

Come grow with us in the US in Thailand in China in Korea in the Philippines in Taiwan in Hong Kong

Sources and Links

VietNam Announces Increased Documentation Requirements

Published on: May 24th, 2021

On May 15, 2021, the VietNamese Ministry of Health (MOH) released new Guidance announcing Class B, C, and D devices will need to submit their applications in accordance with the ASEAN Common Submission Dossier Template (CSDT) format. The announcement goes into effect on January 2022 but the MOH has stated that they will begin accepting CSDT format ahead of time, greatly benefiting manufacturers that already have the CSDT documentation in order. Manufacturers will also need to show evidence of sufficient cybersecurity for products connected to the internet and all applications will need to be signed and stamped by a local license holder, like Asia Actual.

Leveraging Your CSDT Documentation

While the new process will require more documentation, allowing CSDT applications significantly benefits manufacturers with approvals in countries like Singapore and/or Malaysia (require CSDT). Manufacturers will also be able to submit most of their application in English (VietNamese also accepted) and will not need to submit VietNamese Technical Summaries and IFUs. Some IFUs may still need to be supplied in VietNamese, along with all devices still requiring a VietNamese sub-label. For the latest information on the VietNamese regulatory process, please see our Medical Device Registration page.

Outline of VietNam CSDT Table of Contents

1. Executive Summary

  1. An overview (introductory descriptive information on the medical device, the intended uses and indications for use of the medical device, any novel features and a synopsis of the content of the CSDT);
  2. Commercial marketing history;
  3. Intended uses and indications in labelling;
  4. List of regulatory approval or marketing clearance obtained;
  5. Important safety/performance related information.

2. Essential Principles and Evidence of Conformity with Declaration of Conformity

3. Device Description

  1. Device description & features
  2. Intended Use
  3. Indications
  4. User Manual/Instructions for Use
  5. Contraindications
  6. Warnings
  7. Precautions
  8. Potential adverse effects
  9. Alternative therapy
  10. Materials (VietNamese or English)
  11. Other Relevant Specifications
  12. Other Descriptive Information

4. Summary of Design Verification and Validation Documents (English or VietNamese)

  1. Pre-Clinical Studies
    1. Software verification and validation studies (if applicable)
    2. Medical equipment containing biological materials
  2. Preclinical studies of in vitro reagents, calibrators, and control materials
    1. Analytical Performance
    2. Stability
  3. Clinical Evidence
    1. Literature Review
    2. Clinical Experience Data (not from Clinical Studies)
    3. Clinical Studies

5. Device Labelling

  1. Samples of Labels on the Device and its Packaging
  2. User Manual/Instructions for Use

6. Risk Analysis (English or VietNamese)

7. Manufacturer Information (English or VietNamese)

Come Grow With Us

Asia Actual specializes in helping medical device manufacturers grow their sales in Asia with experienced, bi-lingual commercial and regulatory experts on the ground in each market. Our commercialization experts can help you evaluate the VietNamese market and develop an optimal pricing strategy that can help you grow your sales in the 100-million-person market. Contact Asia Actual today with any questions or support requests.

Blog Posts

China’s NMPA Updates Medical Device Classification Catalogue

China’s National Medical Products Administration (NMPA) maintains a list of all medical device categories called the Medical Device Classification Catalogue. NMPA published a notice on August 17, 2023, that they had released amendments to the Medical Device Classification Catalogue. It’s important for manufacturers to understand these changes as they can significantly impact the cost and time to register medical devices.

Thai FDA Drafting New Guidance for SaMD and AI Device Registration

Thai FDA is drafting new guidelines for AI Regulation. The novel characteristics of artificial intelligence (AI) software cause issues with the medical device registration process in most countries. The Thai Food and Drug Administration (Thai FDA) is working to address this important issue, most recently by hosting a meeting with interested parties on July, 2023, which Asia Actual Thailand employees were invited to attend.

China NMPA Adds 47 Products to Clinical Trial Exemption List

China’s National Medical Products Administration (NMPA) updated its clinical trial exemption list, adding 47 products. The NMPA updates this list every two to three years, with the last amendment in 2021. This brings the total number of clinical trial exempted product categories in China to 1,025.